Iptacopan improves hematologic, clinical outcomes in persistent anemia
The first-in-class oral factor B inhibitor iptacopan improves hematologic and clinical outcomes in anti-C5-treated patients with persistent anemia and in those who have not received complement inhibitors, according to a study ...
Mar 19, 2024
0
0